tradingkey.logo
tradingkey.logo
Suchen

ENDRA Life Sciences Inc

NDRA
Zur Watchlist hinzufügen
5.330USD
+0.330+6.60%
Handelsschluss 06/30, 16:00ETKurse um 15 Minuten verzögert
11.35MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über ENDRA Life Sciences Inc Unternehmen

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Inc Informationen

BörsenkürzelNDRA
Name des UnternehmensENDRA Life Sciences Inc
IPO-datumJun 28, 2017
CEOTokman (Alexander Y)
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse3600 Green Ct Ste 350
StadtANN ARBOR
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl48105
Telefon17343350468
Websitehttps://www.endrainc.com/
BörsenkürzelNDRA
IPO-datumJun 28, 2017
CEOTokman (Alexander Y)

Führungskräfte von ENDRA Life Sciences Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ENDRA Life Sciences Inc?

Die fünf größten Anteilseigner von ENDRA Life Sciences Inc sind: Mr. Anthony DiGiandomenico

Wie viele Institutionen halten Anteile an ENDRA Life Sciences Inc (NDRA)?

Mit Stand vom 2026Q1 halten 30 Institutionen Anteile an ENDRA Life Sciences Inc, mit einem Gesamtmarktwert von etwa 218.33K, was 17.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 137855.00 gestiegen.